Sentences with phrase «medicine company avita»

Just in time for allergy season, allergy medicine company Zyrtec has launched an Alexa skill that shares the daily pollen count for the user's location.

Dresdner Bank, Weleda AG, a large homeopathic medicine company, and 23 kindergartens in Lorrach all purchase 100 percent green power.

Set in a pair of 1895 buildings, which once included the home of the J.C. Ayer patent medicine company, the condo studios opened in 2000 along with a ground - level gallery that shows work by the residents and other local artists.

According to the pet medicine company, Banixx, this is a fairly common health problem with bulldogs, an elongated soft palate happens when the roof of your dog's mouth goes beyond the opening and goes into the larynx and the airways.

VetStem Biopharma, the leading Veterinary Regenerative Medicine Company, has partnered with Dr Jamie Gaynor and Peak Performance Veterinary Group to offer a Regenerative Medicine Center of Excellence.

AxoGen Inc is a regenerative medicine company.

ViaCyte is a privately held, clinical - stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.

SAN DIEGO, June 22, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced two presentations at ISSCR 2016 Annual Meeting.

RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today the publication of a paper out of the University of Calgary in conjunction with co-authors from Kyoto University and the University of North Carolina, which further validates the company's ongoing clinical research using dermal sheath cup (DSC) cells to reverse the effects of pattern baldness.

San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.

Novo Biosciences based of Bar Harbor, Maine is a regenerative medicine company developing small molecule therapies that reactivate and stimulate innate healing abilities in humans and animals.

SAN DIEGO and SAN FRANCISCO, February 23, 2017 — ViaCyte, Inc., a privately - held regenerative medicine company, and Beyond Type 1, a not - for - profit advocacy and education group for those living with type 1 diabetes, today announced a grant from Beyond Type 1 to support ViaCyte's efforts to develop a functional cure for type 1 and other insulin - requiring diabetes.

SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.

ViaCyte is a privately - held, clinical - stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.

San Diego, California, October 6, 2014 — ViaCyte, Inc., a privately - held regenerative medicine company developing a stem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follows:

San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product candidate.

San Diego, May 22, 2017 — ViaCyte, Inc., a privately - held leading regenerative medicine company, announced today $ 10 million in financing to support operations.

SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.

SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.

SAN DIEGO, April 12, 2018 — ViaCyte, Inc., a privately - held regenerative medicine company, today announced President and CEO, Paul Laikind, Ph.D., will present at Alliance for Regenerative Medicine's 6th Annual Cell & Gene Therapy Investor Day in New York.

SAN DIEGO, October 4, 2017 — ViaCyte, Inc., a privately - held regenerative medicine company, today announced upcoming company presentations at the Cell and Gene Meeting on the Mesa and the BIO Investor Forum.

San Diego, California, October 29, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell - derived cell therapy, announced today that the Company was granted over 20 patents worldwide in 2013 thus far, three U.S. and twenty foreign.

SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.

SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.

The two co-founded the lab's first spinoff laboratory in its 115 - year history in 2013, regenerative medicine company Novo Biosciences Inc..

Cynata Therapeutics Limited is an Australian clinical - stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus ™ stem cell technology platform.

«I think this is an extremely important — and solid — paper,» says stem cell researcher Robert Lanza, vice president of research and scientific development at Applied Cell Technology, a regenerative medicine company headquartered in Alameda, Calif., who did not take part in the study.

A Chinese regenerative medicine company will provide financial support, according to the account.

A traditional Chinese medicine company and a waste management group have joined the flood of firms from China aiming to list on the ASX.

Tempus is a precision medicine company that uses a machine learning health care data analytics platform to enable physicians to deliver personalized care to cancer patients.

Omada Health is a digital behavioral medicine company that helps people change habits that put them at risk for preventable chronic conditions.

3DS is a personalized medicine company with a software platform based on the three - dimensional analysis of chromosomal signatures.

Just in time for allergy season, allergy medicine company Zyrtec has launched an Alexa skill that shares the daily pollen count for the user's location.

• Fortuna Fix, a Canada - based regenerative medicine company, raised $ 25 million in Series B funding.

Perth - based regenerative medicine company Avita Medical says it will be able to focus more on its core ReCell technology after completing the sale of its respiratory business for $ 2.47 million.

Regenerative medicine company Avita Medical has raised $ 10 million from investors to support the commercialisation of its ReCell device, which is being trialled by a US government agency.

«Personalized medicine companies [have been] trying to deal with this for going on 2 years and keep expressing a lot of frustration,» Sauer says.

The 2017 Annual Data Report details industry - specific statistics and trends from more than 850 leading cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide.

Transcriptic CEO Max Hodak says his company's services have appealed most to personalized medicine companies, such as De Silva's, and to synthetic biology companies that are tweaking the DNA of microorganisms to make them produce useful substances.

For personalized medicine companies like Optimal Medicine Ltd., the patents are about protecting billions of dollars invested in years of research.

Since that deal began in 2015, the GSK Consumer Healthcare team has been closely involved in the legal and operational aspects of integrating two distinct legacy cultures together under a single business unit to form the leading over-the-counter medicines company in the world.

Not exact matches

A crop of young biotech companies is sprouting up to develop medicines.

So many companies have developed such increasingly effective medicines, such as those that treat more hep C strains with far shorter treatment regimens, that Gilead — a pioneer in the field with Sovaldi and Harvoni — is projecting $ 3.5 billion to $ 4 billion in U.S. sales from these kinds of drugs in 2018, a dramatic drop from nearly $ 13 billion in 2015.

Three rival companies, founded by scientific pioneers in this field — Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics — have gone public this year, and together command a market cap of nearly $ 1.7 billion.

And while true reform will require all the relevant parties — government, industry, and health care consumers themselves — to make major adjustments, an insurgent group of digital health companies is doing its best to drag American medicine into the 21st century kicking and screaming.

Some companies are thinking not just outside the box but outside the planet when it comes to improving medicine.

The company delivers a third of all medicines in North America.

Federal regulations don't allow for - profit companies to practice medicine directly, so 98point6 had to set up smaller corporations in each state.

Keeping an eye on blood test results is what Elizabeth Holmes, founder of the revolutionary blood test company Theranos, thinks will transform medicine and help people find out they are sick sooner in life.

So when she discovered that year two of her rotation would focus mostly on surgery, Holly decided to take a break from medicine and give working for her dad's company a try.